Skip to main content
NCBI home page
Protein & Cell logoLink to Protein & Cell
. 2011 Aug 6;2(7):585–599. doi: 10.1007/s13238-011-1080-8

Selective expansion and enhanced anti-tumor effect of antigen-specific CD4+ T cells by retrovirus-mediated IL-15 expression

Jizhou Lv 1,2, Ning Tao 1, Hao Wu 1, Xiaoman Liu 1, Xia Xu 1, Yingxin Xu 3, Zhihai Qin 1,✉
PMCID: PMC4875243  PMID: 21822803

Abstract

Mounting evidence has demonstrated that CD4+ T cells play an important role in anti-tumor immune responses. Thus, adoptive transfer of these cells may have great potential for anti-cancer therapy. However, due to the difficulty to generate sufficient tumor-specific CD4+ T cells, the use of CD4+ T cells in tumor therapy is limited. It has been found that IL-15 transfection enhances the proliferation and anti-tumor activity of tumor-specific CD8+ T cells, but the effect of IL-15 transfection on CD4+ T cells remains unknown. Here, the effects of retrovirusmediated IL-15 expression in Ova-specific CD4+ T cells from Do11.10 mice were evaluated and it was discovered that IL-15 transfected CD4+ T cells expressed both soluble and membrane-bound IL-15. Retrovirusmediated IL-15 expression led to a selective expansion of antigen-specific CD4+ T cells by inhibiting their apoptosis. In vivo IL-15 transfected CD4+ T cells were more effective in suppressing tumor growth than control retroviral vector transfected ones. To ensure the safety of the method, the employment of thymidine kinase gene made it possible to eliminate these transgenic CD4+ T cells following ganciclovir treatment. Together, we show that IL-15 transfection induced a selective expansion of antigen-specific CD4+ T cells ex vivo and enhanced their tumor-suppression effects in vivo. This has an important significance for improving the efficacy of adoptive T cell therapy.

Keywords: CD4+ T cells, retrovirus vector, IL-15, tumor therapy

References

  1. Abad J.D., Wrzensinski C., Overwijk W., De Witte M.A., Jorritsma A., Hsu C., Gattinoni L., Cohen C.J., Paulos C.M., Palmer D.C., et al. T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother. 2008;31:1–6. doi: 10.1097/CJI.0b013e31815c193f. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bergamaschi C., Rosati M., Jalah R., Valentin A., Kulkarni V., Alicea C., Zhang G.M., Patel V., Felber B.K., Pavlakis G.N. Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem. 2008;283:4189–4199. doi: 10.1074/jbc.M705725200. [DOI] [PubMed] [Google Scholar]
  3. Black M.E., Newcomb T.G., Wilson H.M., Loeb L.A. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc Natl Acad Sci U S A. 1996;93:3525–3529. doi: 10.1073/pnas.93.8.3525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Burkett P.R., Koka R., Chien M., Chai S., Boone D.L., Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8 + T cell homeostasis. J Exp Med. 2004;200:825–834. doi: 10.1084/jem.20041389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cohen P.A., Peng L., Plautz G.E., Kim J.A., Weng D.E., Shu S. CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol. 2000;20:17–56. doi: 10.1615/CritRevImmunol.v20.i1.20. [DOI] [PubMed] [Google Scholar]
  6. Cosman D., Kumaki S., Ahdieh M., Eisenman J., Grabstein K.H., Paxton R., DuBose R., Friend D., Park L.S., Anderson D., et al. Interleukin 15 and its receptor. Ciba Found Symp. 1995;195:221–229. doi: 10.1002/9780470514849.ch15. [DOI] [PubMed] [Google Scholar]
  7. Cox A.L., Skipper J., Chen Y., Henderson R.A., Darrow T.L., Shabanowitz J., Engelhard V.H., Hunt D.F., Slingluff C.L., Jr. Identification of a peptide recognized by five melanomaspecific human cytotoxic T cell lines. Science. 1994;264:716–719. doi: 10.1126/science.7513441. [DOI] [PubMed] [Google Scholar]
  8. Culver K.W., Ram Z., Wallbridge S., Ishii H., Oldfield E.H., Blaese R.M. In vivo gene transfer with retroviral vectorproducer cells for treatment of experimental brain tumors. Science. 1992;256:1550–1552. doi: 10.1126/science.1317968. [DOI] [PubMed] [Google Scholar]
  9. Disis M.L., Gooley T.A., Rinn K., Davis D., Piepkorn M., Cheever M.A., Knutson K.L., Schiffman K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol. 2002;20:2624–2632. doi: 10.1200/JCO.2002.06.171. [DOI] [PubMed] [Google Scholar]
  10. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–854. doi: 10.1126/science.1076514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dunbar P.R., Chen J.L., Chao D., Rust N., Teisserenc H., Ogg G. S., Romero P., Weynants P., Cerundolo V. Cutting edge: rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma. J Immunol. 1999;162:6959–6962. [PubMed] [Google Scholar]
  12. Gattinoni L., Powell D.J., Jr, Rosenberg S.A., Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383–393. doi: 10.1038/nri1842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415–419. doi: 10.1126/science.1088547. [DOI] [PubMed] [Google Scholar]
  14. Judge A.D., Zhang X., Fujii H., Surh C.D., Sprent J. Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8(+) T cells. J Exp Med. 2002;196:935–946. doi: 10.1084/jem.20020772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. June C.H. Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007;117:1466–1476. doi: 10.1172/JCI32446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. June C.H. Principles of adoptive T cell cancer therapy. J Clin Invest. 2007;117:1204–1212. doi: 10.1172/JCI31446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Klebanoff C.A., Finkelstein S.E., Surman D.R., Lichtman M.K., Gattinoni L., Theoret M.R., Grewal N., Spiess P.J., Antony P.A., Palmer D.C., et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T cells. Proc Natl Acad Sci U S A. 2004;101:1969–1974. doi: 10.1073/pnas.0307298101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ladekarl M., Agger R., Fleischer C.C., Hokland M., Hulgaard E.F., Kirkin A., von der Maase H., Petersen M.S., Rytter C., Zeuthen J., et al. Detection of circulating tumor lysate-reactive CD4+ T cells in melanoma patients. Cancer Immunol Immunother. 2004;53:560–566. doi: 10.1007/s00262-004-0502-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Leen A.M., Rooney C.M., Foster A.E. Improving T cell therapy for cancer. Annu Rev Immunol. 2007;25:243–265. doi: 10.1146/annurev.immunol.25.022106.141527. [DOI] [PubMed] [Google Scholar]
  20. Li Y., Zhi W., Wareski P., Weng N.P. IL-15 activates telomerase and minimizes telomere loss and may preserve the replicative life span of memory CD8 + T cells in vitro. J Immunol. 2005;174:4019–4024. doi: 10.4049/jimmunol.174.7.4019. [DOI] [PubMed] [Google Scholar]
  21. Marks-Konczalik J., Dubois S., Losi J.M., Sabzevari H., Yamada N., Feigenbaum L., Waldmann T.A., Tagaya Y. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci U S A. 2000;97:11445–11450. doi: 10.1073/pnas.200363097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. McGill J., Van Rooijen N., Legge K.L. IL-15 transpresentation by pulmonary dendritic cells promotes effector CD8 T cell survival during influenza virus infection. J Exp Med. 2010;207:521–534. doi: 10.1084/jem.20091711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Muranski P., Restifo N.P. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol. 2009;21:200–208. doi: 10.1016/j.coi.2009.02.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., Restifo N.P., Haworth L.R., Seipp C.A., Freezer L.J., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100:8372–8377. doi: 10.1073/pnas.1533209100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Qin Z., Blankenstein T. CD4+ T cell—mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity. 2000;12:677–686. doi: 10.1016/S1074-7613(00)80218-6. [DOI] [PubMed] [Google Scholar]
  26. Quezada S.A., Simpson T.R., Peggs K.S., Merghoub T., Vider J., Fan X., Blasberg R., Yagita H., Muranski P., Antony P.A., et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010;207:637–650. doi: 10.1084/jem.20091918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Quintarelli C., Vera J.F., Savoldo B., Giordano Attianese G.M., Pule M., Foster A.E., Heslop H.E., Rooney C.M., Brenner M.K., Dotti G. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007;110:2793–2802. doi: 10.1182/blood-2007-02-072843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Radfar S., Wang Y., Khong H.T. Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo. J Immunol. 2009;183:6800–6807. doi: 10.4049/jimmunol.0901747. [DOI] [PubMed] [Google Scholar]
  29. Rainov N.G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 2000;11:2389–2401. doi: 10.1089/104303400750038499. [DOI] [PubMed] [Google Scholar]
  30. Schumacher T.N. T-cell-receptor gene therapy. Nat Rev Immunol. 2002;2:512–519. doi: 10.1038/nri841. [DOI] [PubMed] [Google Scholar]
  31. Schumacher T.N., Restifo N.P. Adoptive T cell therapy of cancer. Curr Opin Immunol. 2009;21:187–189. doi: 10.1016/j.coi.2009.03.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sharma S., Cantwell M., Kipps T.J., Friedmann T. Efficient infection of a human T-cell line and of human primary peripheral blood leukocytes with a pseudotyped retrovirus vector. Proc Natl Acad Sci U S A. 1996;93:11842–11847. doi: 10.1073/pnas.93.21.11842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Teague R.M., Sather B.D., Sacks J.A., Huang M.Z., Dossett M.L., Morimoto J., Tan X., Sutton S.E., Cooke M.P., Ohlén C., et al. Interleukin-15 rescues tolerant CD8 + T cells for use in adoptive immunotherapy of established tumors. Nat Med. 2006;12:335–341. doi: 10.1038/nm1359. [DOI] [PubMed] [Google Scholar]
  34. Toes R.E., Ossendorp F., Offringa R., Melief C.J. CD4 T cells and their role in antitumor immune responses. J Exp Med. 1999;189:753–756. doi: 10.1084/jem.189.5.753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Willimsky G., Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature. 2005;437:141–146. doi: 10.1038/nature03954. [DOI] [PubMed] [Google Scholar]
  36. Xie Y., Akpinarli A., Maris C., Hipkiss E.L., Lane M., Kwon E.K., Muranski P., Restifo N.P., Antony P.A. Naive tumorspecific CD4 (+) T cells differentiated in vivo eradicate established melanoma. J Exp Med. 2010;207:651–667. doi: 10.1084/jem.20091921. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Protein & Cell are provided here courtesy of Oxford University Press

RESOURCES